Alfuzosin Hydrochloride

CHEMBL1723 Phase 4 Disetujui Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
425.9 g/mol
LogP
Phase
4

The hydrochloride salt form of alfuzosin, an alpha-1 receptor antagonist used to relax smooth muscle in the prostate and bladder neck to relieve urinary obstruction caused by BPH. This formulation provides the same mechanism of action as the parent compound, improving urine flow and reducing bothersome lower urinary tract symptoms in men.

Berat Molekul

425,9000 g/mol

TPSA

112,00 Ų

Area Terapeutik

Mekanisme Kerja

Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mekanisme

Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.

Struktur 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

COc1cc2nc(N(C)CCCNC(=O)C3CCCO3)nc(N)c2cc1OC.Cl

InChI

InChI=1S/C19H27N5O4.ClH/c1-24(8-5-7-21-18(25)14-6-4-9-28-14)19-22-13-11-16(27-3)15(26-2)10-12(13)17(20)23-19;/h10-11,14H,4-9H2,1-3H3,(H,21,25)(H2,20,22,23);1H

Molecular Formula

C19H28ClN5O4

HBD / HBA

3 / 8

Ikatan yang Dapat Dirotasi

8

Atom Berat

29

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Pertanyaan yang Sering Diajukan

The hydrochloride salt form of alfuzosin, an alpha-1 receptor antagonist used to relax smooth muscle in the prostate and bladder neck to relieve urinary obstruction caused by BPH. This formulation provides the same mechanism of action as the parent compound, improving urine flow and reducing bothersome lower urinary tract symptoms in men.

Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.

Yes, Alfuzosin Hydrochloride is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1723. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 71764. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Penyangkalan Medis

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.